Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome

2024-9-1

Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal Reduction

2024-9-1

Pediatric Sedation Gets a Wake-Up Call

2024-9-1

Significance of B-Type Natriuretic Peptide Level in Patients With Small Left Ventricle

2024-9-1

Effect of Screening for Undiagnosed Atrial Fibrillation on Stroke Prevention

2024-9-1

ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction

2024-9-1

Temporal Trends in Takotsubo Syndrome

2024-9-1

Why Have We Not Been Able to Demonstrate Reduced Mortality in Patients With HFmrEF/HFpEF?

2024-9-1

The Alarming Surge of Atrial Fibrillation in the United States

2024-9-1

Metabolic Surgery Saves Lives

2024-9-1

Effect of Evogliptin on the Progression of Aortic Valvular Calcification

2024-9-1

Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy

2024-9-1

Prediction of Cumulative Exposure to Atherogenic Lipids During Early Adulthood

2024-9-1

Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy

2024-9-1

Finding the right needle in the haystack: the real challenge of AF screening

2024-9-1

Triglycerides and Cardiovascular Risk

2024-9-1

Exploring the Need for Precise MI Adjudication in Clinical Trials

2024-9-1

Rethinking Cholesterol Screening and Management in Young Adults

2024-9-1

Potential for Misapplication of a Uniform vs Sex-Specific High-Sensitivity Cardiac Troponin Threshold

2024-9-1

Competing Risks in Clinical Trials

2024-9-1

Reply

2024-9-1

Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation

2024-9-1

Trusting the True Experts Through Patient-Reported Health Status in Hypertrophic Cardiomyopathy

2024-9-1

Unveiling the Unseen: Myosin Inhibitors Cause Reverse Remodeling of Left Ventricular Macro and Microstructure by CMR

2024-9-1

Contents

2024-9-1

Audio Summary

2024-9-1

Why Has it Been Challenging to Modify Kidney Disease Progression in Patients With Heart Failure?

2024-9-1

Finding Truth in Observational and Interventional Studies in Diabetes and Cardiovascular Disease

2024-9-1

Medical Therapy for Aortic Stenosis

2024-9-1

Genotype-Guided Antiplatelet Therapy

2024-9-1

Prognostic Value of Plasma Immunoglobulin G N-Glycome Traits in Pulmonary Arterial Hypertension

2024-9-1

Contents

2024-9-1

Audio Summary

2024-9-1

Association of Postnatal Opioid Exposure and 2-Year Neurodevelopmental Outcomes in Infants Undergoing Cardiac Surgery

2024-9-1

Reply

2024-9-1

Reply

2024-9-1

Short-Term Effects of Lower Air Temperature and Cold Spells on Myocardial Infarction Hospitalizations in Sweden

2024-9-1

Balancing the Climate Equation

2024-9-1

Bridging Atrial and Ventricular Failure Through Biomarkers

2024-9-1

Echocardiographic changes with Aficamten: A pixel is worth 1024 bits

2024-9-1

Unraveling the Mysteries Surrounding Takotsubo Syndrome

2024-9-1

Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy

2024-9-1

Minimum National Prevalence of Diagnosed Atrial Fibrillation Inferred From California Acute Care Facilities

2024-9-1

Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes

2024-9-1

Bleeding and Thrombosis in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention

2024-9-1

Improving Health Status With SGLT2 Inhibitors Following Worsening Heart Failure

2024-9-1

Fucosylation

2024-9-1

Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure

2024-9-1

The Association of Bradycardic Event Risk With Antiarrhythmic Drugs for Atrial Fibrillation

2024-9-1

Antithrombotic Strategies for Patients With Peripheral Artery Disease

2024-8-26